Zhongsheng Pharmaceutical announced that the holding subsidiary Zongsheng Ruichuang has received a patent certificate issued by the European Patent Office. The invention name is “TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION SAME (tyrosine kinase inhibitor and pharmaceutical composition containing this tyrosine kinase inhibitor)”. The patent number is 3293177. The patent application date is April 7, 2016. The patent holder is Zhongsheng Ruichuang, and the patent period is 20 from the application date year. This patent is a compound patent for the ZSP1603 project, an innovative drug with dual effects for treating idiopathic pulmonary fibrosis (IPF) and malignant tumors developed by Zhongsheng Ruichuang. It is the core patent of this project. The ZSP1603 project is the first small molecule innovative drug with the same target approved for clinical use in the treatment of IPF in China.